/

Empresas

LE

No verificado

LEO Pharma Inc.

Sobre qué escribimos

EventosFarmacéuticaIndustriaSaludSanidad

7 Comunicados de prensa

Ver todos los comunicados de prensa

24/10/2025

Eventos

Análisis de Mercados

Sanidad

Farmacéutica

Salud

LEO Pharma Unveils Data on the U.S. Prevalence of Chronic Hand Eczema at Fall Clinical Dermatology Conference

Fuente

LEO Pharma Inc.

Editor

1.00

0

23/07/2025

ANZUPGO® (delgocitinib) Cream Is Now the First and Only FDA-Approved Treatment for Moderate-to-Severe Chronic Hand Eczema (CHE) in Adults

Fuente

LEO Pharma Inc.

Editor

1.00

0

05/03/2025

Eventos

Análisis de Mercados

Salud

Sanidad

Ciencia

Farmacéutica

LEO Pharma Survey: Dermatology Providers Say Chronic Hand Eczema Is Widely Misunderstood and Inadequately Managed

Fuente

LEO Pharma Inc.

Editor

1.00

0

25/10/2024

Eventos

Industria

Salud

Ciencia

Farmacéutica

Medicina - Varios

LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry® Trial (tralokinumab-ldrm) in Patients with Moderate-to-Severe Atopic Dermatitis (AD) at Fall Clinical 2024

Fuente

LEO Pharma Inc.

Editor

1.00

0

23/10/2024

Eventos

Industria

Higiene alimentaria

Salud

Farmacéutica

Medicina - Varios

Sanidad

LEO Pharma Presents Adbry® (tralokinumab-ldrm) and Delgocitinib Cream Data at 2024 Fall Clinical Dermatology Conference

Fuente

LEO Pharma Inc.

Editor

1.00

0

22/10/2024

Industria

Comunicación

Marketing

Medicina - Varios

Gestión empresarial

Sanidad

Farmacéutica

Salud

LEO Pharma Launches Talk to the Hand Campaign to Raise Awareness of the Impact of Chronic Hand Eczema

Fuente

LEO Pharma Inc.

Editor

1.00

0

17/09/2024

Industria

Sanidad

Farmacéutica

Salud

Adbry® (tralokinumab-ldrm) Autoinjector Now Available for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD) in the U.S.

Fuente

LEO Pharma Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0